Home › Funds › Cormorant Asset Management, LP › NAMS

Cormorant Asset Management, LP position in NAMS

NEWAMSTERDAM PHARMA COMPANY · Health Care

Cormorant Asset Management, LP reported holding 500,000 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY) in its Q2 2026 13F filing — a position valued at US$16.9M, representing 0.87% of its reported portfolio and ranking #28 among its reported holdings. Cormorant Asset Management, LP has disclosed NAMS holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

Latest position (Q2 2026)500.00K sh
Reported value held$16.95M
Portfolio Weight0.87%
First reportedQ1 2024
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Cormorant Asset Management, LP's NAMS position evolved

Cormorant Asset Management, LP first disclosed a stake in NAMS in Q1 2024 at 1,500,000 shares (US$35.5M). The position peaked in Q4 2024 at 3,250,000 shares, worth US$83.5M. Across 10 filings, Cormorant Asset Management, LP increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 500,000 shares valued at US$16.9M — a reduction of -450,000 shares quarter over quarter.. Notable position changes include a 92% trim in Q1 2025 (shares fell 8% over the following quarter), a 770% increase in Q2 2025 (shares rose 50% over the following quarter), a 54% trim in Q4 2025 (shares fell 9% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 1.50M $35.48M New
Q2 2024 2.30M $44.18M Add
Q3 2024 2.47M $41.00M Add
Q4 2024 3.25M $83.53M Add
Q1 2025 250.00K $5.12M Reduce
Q2 2025 2.17M $39.39M Add
Q3 2025 2.17M $61.86M Hold
Q4 2025 1.00M $35.08M Reduce
Q1 2026 950.00K $30.41M Reduce
Q2 2026 500.00K $16.95M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NAMS and 13F data

NAMS (NEWAMSTERDAM PHARMA COMPANY) is a Health Care company. 43 other funds we track also report a position in NAMS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$613.0M), RA CAPITAL MANAGEMENT, L.P. (US$323.7M), FCPM III SERVICES B.V. (US$287.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NAMS

All NAMS fund holders →

FAQ

How long has Cormorant Asset Management, LP held NAMS?

Cormorant Asset Management, LP has disclosed NAMS holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

What is Cormorant Asset Management, LP's current position in NAMS?

As of Q2 2026, Cormorant Asset Management, LP holds 500.00K shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $16.95M, representing 0.87% of its reported portfolio and ranking #28.

Has Cormorant Asset Management, LP been buying or selling NAMS?

In the latest 13F filing (Q2 2026), Cormorant Asset Management, LP reduced its position in NAMS. The position peaked in Q4 2024 at 3.25M shares.

Which other funds hold NAMS?

Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.